Onco360 Chosen as a Specialty Pharmacy Provider for Besremi

PharmaEssentia has chosen Onco360 to be a specialty pharmacy partner for Besremi (ropeginterferon alfa-2b-njft). The FDA recently approved the therapy as a treatment for adult patients with polycythemia vera. This is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

Related: FDA Approves Treatment for Rare Blood Disease

“We are committed to supporting the highly specialized needs of polycythemia vera patients and their physicians across the United States,” Benito Fernandez, chief commercial officer, Onco360, said in a statement.

Polycythemia vera results from abnormal red blood cell proliferation due to genetic mutations involving the Janus Kinase 2 (JAK2) gene. Due to over-production of red blood cells, patients with polycythemia vera have blood which is thicker than normal, potentially resulting in increased risks for thrombosis and reduction in blood flow.

Besremi is a long-acting drug that patients take by injection under the skin once every two weeks.